4.1.5 Specific inhibitors of dihydroceramide desaturase 1 Another possible therapeutic target is the enzyme dihydroceramide desaturase 1 (DES1), which is involved in ceramide production (116)
By targeting 3 hormone pathways, it promises profound weight-loss results and overall health benefits, more than the single or dual agonists achieve
Its a fit for people looking for weight support who arent eligible for GLP-1 meds
They increase satiety and reduce appetite and calorie intake
declares having received consulting honoraria from Amgen, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi, Takeda, Novo Nordisk and Bayer and research grants from the British Heart Foundation, the MRC, the National Institute for Health and Care Research, Public Health England, Merck Sharp & Dohme (MSD), Pfizer, Aegerion, Colgate and Roche